Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 8/20 | 0.59 |
| ▸ | HTR1F | P30939 | 4/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.36 |
| ▸ | CCR3 | P51677 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15501113 | 0.90 | P2RX7 (0.56) | P2RX7HTR1FCCR3 | |
| SCHEMBL1099198 | 0.89 | P2RX7 (0.65) | P2RX7HTR1FGAA | |
| SCHEMBL1100367 | 0.89 | P2RX7 (0.65) | P2RX7HTR1FGAA | |
| SCHEMBL1099744 | 0.89 | P2RX7 (0.65) | P2RX7HTR1FGAA | |
| SCHEMBL1100528 | 0.88 | P2RX7 (0.66) | P2RX7HTR1FCACNA1H | |
| SCHEMBL1099947 | 0.87 | P2RX7 (0.67) | P2RX7CACNA1H | |
| SCHEMBL1100598 | 0.85 | P2RX7 (0.62) | P2RX7 | |
| SCHEMBL1099589 | 0.84 | P2RX7 (0.75) | P2RX7 | |
| SCHEMBL1098988 | 0.84 | P2RX7 (0.75) | P2RX7 | |
| SCHEMBL1099638 | 0.83 | P2RX7 (0.60) | P2RX7HTR1FCACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153809-B2 | Dihydropyridone ureas as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153809-B2 | Dihydropyridone ureas as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153809-B2 | Dihydropyridone ureas as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2012-04-10 | — | — | US | disclosed |
| WO-2010072599-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | P2RY1, P2RX1, P2RX3 | P2RX7 5/4885HTR1F 160/4885BCHE 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.